INTRODUCTION {#s1}
============

Lovastatin is used for the treatment of hypercholesterolemia because it inhibits HMG-CoA reductase, and thus prevents HMG-CoA\'s conversion into mevalonic acid \[[@R1]\]. Independent of cholesterol-lowering activity, there are increasing evidences that statins have a potential benefit against cardiovascular diseases (CVD). Oxidative stress is believed to cause endothelial dysfunction, an early event and a hallmark in CVD, including atherosclerosis and hypertension \[[@R2]--[@R4]\]. At this standpoint, it is widely accepted that statins prevent endothelial dysfunction by decreasing oxidative stress in vascular cells. However, the targets for stain-reduced oxidative stress in CVD have not been completely elucidated.

Our and other\'s previous studies have proven that activation of proteasome links to oxidative stress and consequent endothelial dysfunction in CVD \[[@R4]--[@R6]\]. Proteasomes are responsible for the degradation of a large number of protein targets throughout eukaryotic cells. The function of proteasomes is regulated by activators that bind to the ends of the 20S core catalytic particle in a single or double fashion and open the ends of the core proteasome to allow entry of protein targets. As one of proteasome activators (PAs), PA200 is broadly expressed in mammalian tissues and it has been suggested to play a crucial role in response to DNA damage \[[@R7], [@R8]\].

MicroRNA (miRs) are approximately 20-nucleotide, single-stranded RNA molecules that target mRNA through partial complementarity and regulate gene expression through inhibition of translation or transcript degradation. Recently, Anna S *et al* reported that microRNAs plays an important role in the regulation of proteasome activity \[[@R9]\]. Furthermore, miR-29b replacement inhibits proteasomes in myeloma cells by targeting PSME4 that encodesPA200 \[[@R10]\]. Available data suggest that statin, such as lovastatin, exerts its effects by inhibiting the proteasome activity in osteoblast, and vascular endothelial and smooth muscle cells \[[@R11], [@R12]\]. Thus, it is interesting to establish if statin via regulation of miR-29b inhibits proteasome activity in CVD.

In the current work, we characterized how lovastatin regulates PA200 and determined the importance of miR-29b in oxidative stress-mediated CVD. Here we report that lovastatin increases miR-29b, resulting in reduction of PA200 and consequent oxidative stress and endothelial dysfunction in rat models of diabetes, dyslipidemia, and hyperhomocysteinemia.

RESULTS {#s2}
=======

Lovastatin increases miR-29b expression in endothelial cells {#s2_1}
------------------------------------------------------------

To investigate whether lovastatin increases miR-29b expression in endothelial cells, we firstly treated cultured HUVECs with varying time-points of lovastatin (10 μM) for 0.5 to 24 hours. As shown in Figure [1A](#F1){ref-type="fig"}, the levels of miR-29b gradually increased beginning from 6 hours and reached peak levels at 24 hours in endothelial cells.

![Lovastatin increases miR-29b expression and decreases proteasome activity in endothelial cells, which is in time/dose-dependent manner\
Cultured HUVECs were incubated with lovastatin as indicated time or concentration. HUVEC cell lysate was subjected to perform qRT-PCR analysis of miR-29b and measurement of proteasome activity. (**A**) Time course of lovastatin (10 μM) in miR-29b expression. (**B**) Dose course of lovastatin (24 hours) in miR-29b expression. (**C**) Time course of lovastatin in proteasome activity. (**D**) Dose course of lovastatin in proteasome activity. Data were expressed by mean ± sem. N is 3 in each group. \**P* \< 0.05 *VS* Control group (Point 0). (**E** and **F**) HUVECs were incubated with compound C (Comp C, 1 μM) for 30 minutes followed by lovastatin (10 μM) treatment for 24 hours. The levels of p-AMPK in E and miR-29b in F were analyzed by western blot and RT-qPCR, respectively. N is 3 in each group. \**P*\<0.05 VS Control. NS indicates no significance.](oncotarget-08-9021-g001){#F1}

The dose-dependent effects of lovastatin on miR-29b expression were next examined in endothelial cells. In Figure [1B](#F1){ref-type="fig"}, lovastatin at 1 μM significantly enhanced miR-29b expression. Increasing concentrations of lovastatin on (5-50 μM) further enhanced miR-29b expression. These observations indicate that lovastatin increases miR-29b expression in endothelial cells, which is in time- or dose-dependent manner.

Lovastatin decreases proteasome activity in endothelial cells {#s2_2}
-------------------------------------------------------------

The impacts of lovastatin on the proteasome activity *in vitro* were determined by exposing endothelial cells to lovastatin as indicated concentrations or times. As depicted in Figure [1C](#F1){ref-type="fig"}, lovastatin at 10 μM started to decrease proteasome activity at 6 hours to 24 hours. Similarly, 24-hour incubation of lovastatin at 5-50 μM markedly reduced proteasome activity in endothelial cells (Figure [1D](#F1){ref-type="fig"}), consistent with previous reports \[[@R11]--[@R15]\]. Based on these observations, 10 μM and 24-hour incubations of lovastatin were selected in most of the following experiments in endothelial cells.

Lovastatin via AMPK activation increases the levels of miR-29b in endothelial cells {#s2_3}
-----------------------------------------------------------------------------------

Lovastatin has been reported to activate AMPK via phosphorylation in endothelial cells \[[@R16]\]. Thus, we hypothesized that lovastatin via AMPK activation upregulates miR-29b expression in endothelial cells. To test this notion, we treated cells with compound C to inhibit AMPK activity. As shown in Figure [1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}, lovastatin upregulated both miR-29b and p-AMPK expressional levels in cells treated with vehicle (DMSO), but not in cells treated with compound C, demonstrating that lovastatin via AMPK activation upregulated miR-29b expression in HUVECs.

MiR-29b mediates lovastatin-induced suppression of proteasome activity in endothelial cells {#s2_4}
-------------------------------------------------------------------------------------------

To investigate whether miR-29b mediates the suppression of lovastatin on proteasome activity in endothelial cells, HUVECs were infected with lentivirus expressing scrambled microRNA, anti-miR-29b and pre-miR-29b. As presented in Figure [2A](#F2){ref-type="fig"}, lovastatin still dramatically reduced proteasome activity in HUVECs infected with scr-miR lentivirus, but not in endothelial cells infected with anti-miR-29b lentivirus. The suppression of lovastatin on proteasome activity was further enhanced if cells were overexpressed with miR-29b. This indicates that the reduction of proteasome activity induced by lovastatin is mainly due to upregulation of miR-29b in endothelial cells.

![PA200 is a target of miR-29b to regulate proteasome activity in lovastatin-treated endothelial cells\
(**A**) Cultured HUVECs were infected with lentivirus expressing scrambled microRNA, anti-miR-29b and pre-miR-29b, and then incubated with lovastatin (10 μM) for 24 hours. Cell lysate was subjected to assay proteasome activity by measuring ATP-dependent degradation of proteasome fluorescence substrate. (**B**) The predictions of miR-29b targeting 3′-UTR of PSME4 by Target Scan. (**C**) PA200 protein expression was detected by Western blotting in cells from A. Data were expressed by mean ± sem. N is 3 in each group. \**P* \< 0.05 *VS* Control or scr-miR group. ^\#^*P* \< 0.05 *VS* Pre-miR-29b alone group. (**D** and **E**) HUVECs were infected with (**D**) lentivirus containing PA200 cDNA or (**E**) transfected with PA200 siRNA, and then incubated with lovastatin (10 μM) for 24 hours. Cell lysate was subjected to assay proteasome activity. N is 3 in each group. \**P* \< 0.05 *VS* Vector or scr-miR group. NS indicates no significant.](oncotarget-08-9021-g002){#F2}

PA200 is a target of miR-29b in endothelial cells treated with lovastatin {#s2_5}
-------------------------------------------------------------------------

PA200 has been identified as a target of miR-29b through PSME4 gene that encodes \[[@R10]\]. Thus, it was interesting to evaluate if lovastatin via upregulation of miR-29b reduces PA200 gene expression in endothelial cells. By performing Target Scan, we predicted the 3′-UTR of PSME4 as a miR-29b target (Figure [2B](#F2){ref-type="fig"}). Further, lovastatin significantly decreased PA200 protein level in endothelial cells. However, the downregulation of PA200 induced by lovastatin was abolished by anti-miR-29b and further amplified by overexpression of pre-miR-29b in HUVECs (Figure [2C](#F2){ref-type="fig"}), suggesting that a decreased PA200 by lovastatin may attribute to miR-29b.

Inhibition of proteasome activity by lovastatin is PA200-dependent {#s2_6}
------------------------------------------------------------------

PA200 is broadly expressed in mammalian cells, which is a proteasome activator \[[@R7], [@R10], [@R17]\]. We hypothesized that reduction of PA200 by lovastatin inhibits proteasome activity. To test this notion, endothelial cells were infected with lentivirus containing PA200 cDNA to establish PA200-overexpressed cell model (Figure [2D](#F2){ref-type="fig"}). Although lovastatin reduced proteasome activity in vector-infected cells, it failed to inhibit proteasome activity in endothelial cells with overexpression of PA200.

The role of PA200 in lovastatin-induced miR29b-mediated inhibitory effects on proteasome activity was further confirmed by decreasing the expression of PA200. As shown in Figure [2E](#F2){ref-type="fig"}, knockdown of PA200 mirrored the effects of lovastatin on suppression of proteasome activity. Anti-miR-29b, as an inhibitor of miR-29b, increased proteasome activity, which is opposite to lovastatin. However, anti-miR-29b did not alter proteasome activity in HUVECs if PA200 is deficiency by siRNA inference. Collectively, these data suggest that PA200 mediates the inhibition of proteasome activity by miR-29b in lovastatin-treated cells.

Blockage of miR-29b abolishes the effects of lovastatin on suppressing ROS productions induced by multiple cardiovascular risk factors {#s2_7}
--------------------------------------------------------------------------------------------------------------------------------------

We previously have reported that increased proteasome activity degrades IKBα or GTP cyclohydrolase I to induce oxidative stress in endothelial cells \[[@R4], [@R5]\]. We next determined whether suppression of proteasome activity inhibits oxidative stress in endothelial cells. As shown in Figure [3A](#F3){ref-type="fig"}, multiple cardiovascular risk factors, including ox-LDL, H~2~O~2~, TNFα, HTL and HG, dramatically increased ROS productions by measuring DHE fluorescent density in endothelial cells. As expected, Treatment with lovastatin reversed these abnormalities.

![Lovastatin via upregulation of miR-29b suppresses oxidative stress in endothelial cells treated with oxidized low density lipoprotein (ox-LDL), hydrogen peroxide (H2O2), tumor necrosis factor alpha (TNFα), homocysteine thiolactone (HTL) or high glucose (HG)\
(**A**) Cultured HUVECs were pretreated lovastatin (10 μM) for 30 minutes followed by co-incubation with ox-LDL (100 mg/l), H~2~O~2~ (50 μM), TNFα (10 ng/ml), HTL (1 mM) or HG (30 mM) for 24 hours. ROS productions were determined by measuring DHE fluorescent intensity. Data were expressed by mean ± sem. N is 3 in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* ox-LDL, H~2~O~2~, TNFα, HTL or HG alone group. (**B**) HUVECs were infected with lentivirus containing with scrambled microRNA, anti-miR-29b and pre-miR-29b, and then incubated with lovastatin (10 μM) for 30 minutes followed by ox-LDL (100 mg/l) or HG (30 mM) for 24 hours. ROS productions were determined by measuring DHE fluorescent intensity. Data were expressed by mean ± sem. N is 3 in each group. \**P* \< 0.05 *VS* scrambled microRNA alone group. ^\#^*P* \< 0.05 *VS* scrambled microRNA plus ox-LDL or HG alone group. NS indicates no significant.](oncotarget-08-9021-g003){#F3}

To investigate the role of miR-29b in lovastatin-suppressed oxidative stress, we tested the effects of lovastatin in cells deficient of miR-29b. As shown in Figure [3B](#F3){ref-type="fig"}, lovastatin reduced ROS productions induced by ox-LDL or HG in scr-miR-infected cells. Importantly, these suppressions were abolished in cells infected with anti-miR-29b lentivirus. In sum, these data suggest that upregulation of miR-29b by lovastatin suppresses oxidative stress in endothelial cells.

Lovastatin prevents endothelial dysfunction induced by multiple oxidants in isolated rat descending aortic arteries *ex vivo* {#s2_8}
-----------------------------------------------------------------------------------------------------------------------------

Oxidative stress is believed to cause endothelial dysfunction, which is defined by impaired endothelium-dependent relaxation, is an early marker for CVD \[[@R2]\]. Thus, it was interesting to evaluate if lovastatin prevents endothelial dysfunction. We first tested this on *ex vivo* experiments in isolated rat descending aortic arteries. By incubations of rat aortic rings with LPC of the major metabolite of ox-LDL (Figure [4A](#F4){ref-type="fig"}), DPPH of an exogenous free radical (Figure [4B](#F4){ref-type="fig"}), and H~2~O~2~ of an endogenous ROS (Figure [4C](#F4){ref-type="fig"}), all oxidants impaired acetylcholine-induced endothelium-dependent relaxation. Pre-incubation of aortic rings with lovastatin bypassed these detrimental effects induced by oxidants including LPC, DPPH and H~2~O~2~ (Figure [4D](#F4){ref-type="fig"}).

![Lovastatin prevents endothelial dysfunction induced by multiple oxidants in isolated rat descending aortic arteries\
The isolated rat aortic rings were preincubated with lovastatin (10 μM) for 30 minutes and then exposed to (**A**) LPC (4 mg/l), (**B**) DPPH (1 μM), and (**C**) H~2~O~2~ (50 μM) for 2 hour. The endothelium-dependent relaxation induced by acetylcholine was assayed by organ chamber. (**D**) MDA content by TBA method. All data were expressed as mean ± SEM. N is 5 in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* LPC, DPPH or H~2~O~2~ alone.](oncotarget-08-9021-g004){#F4}

Lovastatin improves endothelial dysfunction in dyslipidemia rats {#s2_9}
----------------------------------------------------------------

We next evaluate if lovastatin prevents endothelial dysfunction *in vivo*. LDL in dyslipidemia patients which accumulates in the arterial wall is crucial to trigger the initiation and progression of atherosclerotic plaque. By using model of dyslipidemia which was established by us and others \[[@R18], [@R19]\], we found that a single injection of native LDL, but not vehicle of lovastatin or saline, markedly decreased endothelium-dependent relaxation (Figure [5A](#F5){ref-type="fig"}). Administration of lovastatin at 2 or 4 mg/kg/day, prior to LDL injection, rescued LDL-induced impairment of endothelial function in rats (Figure [5B](#F5){ref-type="fig"}). Besides, LDL-induced oxidative stress, as decreased SOD activity (Figure [5C](#F5){ref-type="fig"}) and increased MDA level in serum (Figure [5D](#F5){ref-type="fig"}), were also reversed by lovastatin treatment. Taking these data together, it demonstrates that lovastatin prevents endothelial dysfunction in dyslipidemia model, which is related to suppression of oxidative stress.

![Lovastatin attenuates LDL-induced endothelial dysfunction in rats\
SD Rats were received treated by intraperitoneal injection with lovastatin (2 or 4 mg/kg) or vehicle once daily for 6 consecutive days followed by a single injection of n-LDL (4 mg/kg) or Saline by sublingual vein. (**A**) The endothelium- dependent relaxations induced by acetylcholine in control and LDL rats. (**B**) Does-course of lovastatin in acetylcholine-induced vasorelaxation in LDL-injected rats. (**C**) Serum SOD activity and (**D**) Serum MDA content were assayed in all rats. All data were expressed as mean ± SEM. N is 10-15 in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* LDL-injected rats.](oncotarget-08-9021-g005){#F5}

Lovastatin improves endothelial dysfunction induced by high glucose both *ex vivo* and *in vivo* {#s2_10}
------------------------------------------------------------------------------------------------

We then investigated whether these actions of lovastatin on suppression of oxidative stress and protection of endothelial function would be shared by other animal models with high risk factors of CVD. To this end, we used HG or hyperglycemia model to determine the effect of lovastatin on endothelial function in diabetic rats. As indicated in Figure [6A](#F6){ref-type="fig"}, HG but not high osmatic decreased acetylcholine-induced vessel relaxation in isolated rat aortic rings. This was attenuated by lovastatin in dose-dependent manner (Figure [6B](#F6){ref-type="fig"}).

![Lovastatin reduces oxidative stress and improves endothelial dysfunction induced by high glucose both *ex vivo* and *in vivo*\
*Ex vivo:* (**A** and **B**) Isolated aortic rings from rats were incubated with high glucose (HG, 30 mM), lovastatin (10 μM), mannitol (30 mM), HG plus lovastatin (10-40 μM). The endothelium-dependent relaxations were induced by acetylcholine in all aortic rings. All data were expressed as mean ± SEM. N is 5-10 rings in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* HG-treated rings. *In vivo:* (**C**-**F**) Rat models of diabetes were induced by injection of STZ (50 mg/kg/day, I.P., 5 consecutive days) and then received administration of lovastatin (5, 10 mg/kg/day) for 6 weeks. (**C**) Acetylcholine-induced vasorelaxation, (**D**) serum GSH-PX activity, (**E**) serum MDA level, and (**F**) serum SOD activity were determined. All data were expressed as mean ± SEM. N is 10-15 in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* Diabetes group.](oncotarget-08-9021-g006){#F6}

The *ex vivo* effects of lovastatin were further confirmed by *in vivo* experiments (Figure [6C](#F6){ref-type="fig"}). Type 1 diabetes model in rat was induced by injection of STZ. Lovastatin dose-dependently rescued the impairment of endothelial function induced by hyperglycemia. Furthermore, increased MDA level (Figure [6D](#F6){ref-type="fig"}) and decreased SOD and GSH-Px activities (Figure [6E](#F6){ref-type="fig"} and Figure [6F](#F6){ref-type="fig"}) in blood from diabetic rats were reversed by lovastatin treatments.

Lovastatin normalizes hyperhomocysteinemia-induced endothelial dysfunction both *ex vivo* and *in vivo* {#s2_11}
-------------------------------------------------------------------------------------------------------

We also examined the effects of lovastatin on hyperhomocysteinemia model, which is an independent risk factor of CVD. We used HTL, which is the most reactive form in all of homocysteinemia metabolites \[[@R20]\] and has been demonstrated to induce endothelial dysfunction by us \[[@R21]\], to treated aortic rings isolated from SD rats. Consistently, HTL damaged endothelial function as indication of decreased endothelium-dependent relaxation (Figure [7A](#F7){ref-type="fig"}). Lovastatin dose-dependently prevented HTL-impaired acetylcholine-induced vasorelaxation in isolated rat aortic artery, as well as normalizations of redox status (Figure [7B](#F7){ref-type="fig"} and Figure [7C](#F7){ref-type="fig"}).

![Lovastatin inhibits hyperhomocysteinemia-induced oxidative stress and endothelial dysfunction both *ex vivo* and *in vivo*\
*Ex vivo:* (**A**-**C**) Isolated aortic rings from rats were incubated with homocysteine thiolactone (HTL, 1 mM) with or without lovastatin (10-40 μM). (**A**) Acetylcholine-induced endothelium-dependent relaxation, (**B**) MDA content and (**C**) SOD activity in homogenates of aortic tissues were assayed. All data were expressed as mean ± SEM. N is 5-10 rings in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* HTL-treated rings. *In vivo:* (**D**-**G**) SD rats were intragastrically gavaged with HTL (50 mg/kg/day) and received administration of lovastatin (10, 40 mg/kg/day) for 8 weeks. (**D**) Acetylcholine-induced vasorelaxation, (**E**) serum MDA level, (F) serum SOD activity, and (**G**) serum GSH-PX activity were determined. All data were expressed as mean ± SEM. N is 10-15 in each group. \**P* \< 0.05 *VS* Control group. ^\#^*P* \< 0.05 *VS* HTL group.](oncotarget-08-9021-g007){#F7}

Like the effects of lovastatin in diabetes, lovastatin also eliminated all HTL-induced harmful effects in dose-dependent manner, including reduction of acetylcholine-induced vasorelaxation (Figure [7D](#F7){ref-type="fig"}), enhancement of serum MDA level (Figure [7E](#F7){ref-type="fig"}), and decreased activities of SOD and GSH-Px (Figure [7F](#F7){ref-type="fig"} and Figure [7G](#F7){ref-type="fig"}) in blood from rats fed with HTL, further supporting that prevention of endothelial dysfunction by lovastatin is a common mechanism to prevent or treat CVD induced by multiple cardiovascular risk factors.

Lovastatin reduces ROS productions in models of diabetes, dyslipidemia, and hyperhomocysteinemia in rats {#s2_12}
--------------------------------------------------------------------------------------------------------

Finally, we evaluated the effects of lovastatin on ROS productions in rat models with multiple cardiovascular risk factors. As shown in Figure [8A](#F8){ref-type="fig"}, all risk factors of CVD including diabetes, dyslipidemia, and hyperhomocysteinemia, dramatically increased ROS productions in carotid arteries from rats. Noticeably, administration of lovastatin abolished these alterations in those rats, indicating that reduction of oxidative stress by lovastatin is a common mechanism in the prevention of endothelial dysfunction in CVDs.

![Lovastatin reduces ROS productions in models of diabetes, dyslipidemia, and hyperhomocysteinemia in rats\
(**A**) ROS productions were determined by staining DHE in alive carotid arteries from models of diabetes, dyslipidemia, and hyperhomocysteinemia in rats. The picture is a representative picture from 5 rats. (**B**) Proposed mechanism of lovastatin on protections of endothelial function.](oncotarget-08-9021-g008){#F8}

DISCUSSION {#s3}
==========

In this study, we have defined a common mechanism of lovastatin to prevent endothelial dysfunction in different models of CVD, in which lovastatin-increased miR-29b expression is linked to the suppression of oxidative stress, a key step to cause endothelial dysfunction in CVD. To the best of our knowledge, this is the first report on the impacts of statin on endothelial dysfunction in multiple animal models with risk factors of cardiovascular disease.

The major finding in this paper is that lovastatin increases miR-29b expression in vascular endothelial cells, which mediates the beneficial effects of lovastatin in CVD. Statins have been reported to produce the lowering-lipid effects via inhibition of HMG-CoA reductase. In the present study, we firstly reported that lovastatin increases miR-29b expression to prevent endothelial dysfunction. Although statins have been identified to inhibit proteasome activity in many kinds of mammalian cells \[[@R12], [@R14], [@R22]\], including endothelial cells \[[@R11]\], we exploited a novel mechanism in which lovastatin increases miR-29b expression to prevent endothelial dysfunction. Emerging data support that micro-RNA, including miR-22 \[[@R23]\], miR-34a \[[@R24]\], miR-155 \[[@R25]\], miR-221/222 \[[@R26]\], is important for the multiple functions of statins, which is independent of HMG-CoA reductase inhibition. Of note, how lovastatin increases miR-29b expression in endothelial cells needs further investigations.

The study also indicates that lovastatin via suppression of oxidative stress prevents endothelial dysfunction in multiple models of CVD with high risk factors. Recently, Xu *et al* reported that oxidative stress linking to proteasome activation is a cardinal feature of endothelial dysfunction shared by different models of CVD \[[@R27]\]. In this study, we not only provided evidences to further support this viewpoint, but also uncover the common mechanism of lovastatin to protect against endothelial dysfunction of an early marker for multiple CVD, such as atherosclerosis and hypertension. Although statin is effective to lower blood lipid level in patients with hyperlipidemia, the functions of statin in CVD are largely controversy. In this study, we provide solid evidences, at various setting ranging from *in vitro* and *ex vivo* to whole animal models, to verify that lovastatin improves endothelial dysfunction in rats with hyperglycemia, dyslipidemia and hyperhomocysteinemia, in which all are common high risk factors of CVD. From this angle of endothelial function, statin is absolutely considerable to prevent CVD, such as atherosclerosis and hypertension.

In summary, this study reveals a novel and common mechanism of lovastatin to prevent endothelial dysfunction. As present in Figure [8B](#F8){ref-type="fig"}, lovastatin increases miR-29b expression to downregulate PA200 protein, resulting in proteasome inactivation and subsequent suppression of oxidative stress. In this way, lovastatin prevents endothelial dysfunction in rats with common high risk factors of CVD. Therefore, the current study will open new avenue to investigate the effects of miR-29b in CVD and also provide some insights to drug design for CVD in that targeting miR-29b to improve the outcomes of medical intervention, such as statin.

MATERIALS AND METHODS {#s4}
=====================

Animals {#s4_1}
-------

Male Sprague-Dawley (SD) rats (8 ± 2 weeks old, 180 ± 20 g) were purchased from the Center of Experiment Animals, Central South University (Changsha, China). Rats were housed in temperature-controlled cages with a 12-hour light-dark cycle. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was reviewed and approved by the University of Central South Animal Care and Use Committee.

Materials {#s4_2}
---------

Lovastatin, lysophosphatidylcholine (LPC), hydrogen peroxide (H~2~O~2~), tumor necrosis factor alpha (TNFα), homocysteine thiolactone (HTL), D-glucose, mannitol, 1.1-dipheyl-2-picryl hydrazyl (DPPH), streptozotocin (STZ), acetylcholine, and phenylephrine were purchased from Sigma-Aldrich Company or Caymen chemical Company. Primary antibodies against PA200, p-AMPK, AMPK, and GAPDH, and secondary antibodies were obtained from Cell Signaling Company. Commercial kits malondialdehyde (MDA), superoxide dismutase (SOD) and Glutathione peroxidase (GSH-Px) were purchased from Jian-Cheng Bioengineering Institute (Nanjing, China). Oxidized low density lipoprotein (ox-LDL) was obtained from Guangzhou Yiyuan Biotech Co. Ltd. (Guangzhou, China). All drug concentrations are expressed as final working concentrations in the buffer.

Preparation of LDL {#s4_3}
------------------

As described previously \[[@R28]\], LDL was isolated by discontinuous density gradient ultracentifugation method from fresh human plasma in healthy normal-lipidemic donors. Edetic acid of 10 μM was added to the plasma to avoid autoxidation and its density was adjusted to 1.065 g/L by adding solid NaBr and the samples were ultracentrifugated (200 000×*g*, 20 h, 4°C). The purity of LDL was identified by agarose gel electrophoresis and the protein content was determined by the BCA method. The purified LDL was dialyzed for 24 h against 2 L phosphate buffer solution (pH 7.4, 0.2 M) at 4°C. Dialyzed LDL was frozen at -70°C. Before the injection of n-LDL into the animals, the LDL was sterilized after passing through a 0.45-μm filter and was kept on ice until injected.

Cell culture {#s4_4}
------------

Human umbilicus vein endothelial cells (HUVECs) were obtained from Clonetics Inc. (Walkersville, MD, USA). Cells were grown in endothelial basal medium supplemented with 2% fetal bovine serum and penicillin (100 u/ml), and streptomycin (100 μg/ml). Cultured cells were used between passages 3 and 8. All cells were incubated in a humidified atmosphere of 5%CO~2~ +95% air at 37°C. When 70-80% confluent, the cells were treated with different agents.

Generation of lentivirus vector and infection to cells {#s4_5}
------------------------------------------------------

The lentivirus containing scr-miR, anti-miR29b, pre-miR29b, or full length PA200 cDNA, was generated by GenePharma Company (Shanghai, China). HUVECs were infected with lentivirus overnight in antibiotics-free medium supplemented with 2% FBS. The cells were then washed and incubated in fresh medium for an additional 12 h before experimentation as described previously \[[@R29]\].

Transfection of siRNA into cells {#s4_6}
--------------------------------

Transient transfection of siRNA was carried out according to Santa Cruz\'s protocol. Briefly, the siRNAs were dissolved in siRNA buffer (20 mM KCl; 6 mM HEPES, pH 7.5; 0.2 mM MgCl~2~) to prepare a 10 μM stock solution. Cells grown in 6-well plates were transfected with siRNA in transfection medium containing liposomal transfection reagent (Lipofectamine RNAiMax, Invitrogen, Shanghai branch, China). For each transfection, 100 μl transfection medium containing 4 μl siRNA stock solution was gently mixed with 100 μl transfection medium containing 4 μl transfection reagent. After 30-min incubation at room temperature, siRNA-lipid complexes were added to the cells in 1.0 ml transfection medium, and cells were incubated with this mixture for 6 h at 37°C. The transfection medium was then replaced with normal medium, and cells were cultured for 48h.

Establishments of diabetes, dyslipidemia, and hyperhomocysteinemia {#s4_7}
------------------------------------------------------------------

For diabetic model of rats, a low-dose STZ (50 mg/kg/day, 5 consecutive days, I.P.) in induction regimen was used to induce pancreatic islet cell destruction and persistent hyperglycemia as previously described by the Animal Models of Diabetic Complications Consortium (<http://www.amdcc.org>). Hyperglycemia was defined as a random blood glucose level of \> 300 mg/dl for \>2 weeks after injection. The dyslipidemia model in rats has been established by us previously \[[@R18]\]. In brief, native LDL dissolved in saline was injected to rat (4 mg/kg) via the sublingual vein under ether anesthesia. For establishment of hyperhomocysteinemia, rats were intragastrically gavaged with HTL (50mg/kg/day) for 8 weeks with normal diet as described previously \[[@R21]\].

RNA quantification {#s4_8}
------------------

As described previously \[[@R30]\], total RNA was isolated using a Trizol-based (Invitrogen) RNA isolation protocol. RNA was quantified by Nanodrop (Agilent Technologies), and RNA and miRNA quality were verified using an Agilent 2100 Bioanalyzer (Agilent Technologies). First strand cDNA synthesis was performed for each RNA sample using the Superscript II RT Kit (Applied Biosystems, New York, USA). Real time quantitative polymerase chain reaction was performed using Taqman PCR reagents (Applied Biosystems), and the primers for miR-29b were designed according to the manufacturer\'s recommendations. The relative amount of miRNA was standardized against U6 snRNA, and the fold change for miR-29b was calculated using the 2-DD computed tomography method.

Proteasome activity assay {#s4_9}
-------------------------

Cells were washed with PBS and then with buffer I (50 mM Tris, pH 7.4, 2 mM DTT, 5 mM MgCl~2~, 2 mM ATP). The cells were then made into pellets by centrifugation. Homogenization buffer (50 mM Tris, pH 7.4, 1 mM DTT, 5 mM MgCl~2~, 2 mM ATP, 250 mM sucrose) was added, and cells were subjected to a vortex for 1 minute. Cell debris was removed by centrifugation at 1000g for 5 minutes followed by 10 000g for 20 minutes. Protein (100 μg) from each sample was diluted with buffer I to a final volume of 1000 μl. The fluorogenic proteasome substrate Suc-LLVY-7-amido-4-methylcoumarin was added at a final concentration of 80 μM in 1% DMSO. Cleavage activity was monitored continuously by detection of free 7-amido-4-methylcoumarin with a fluorescence plate reader (Gemini, Molecular Devices, Sunnyvale, CA, USA) at 380/460 nm at 37°C.

Western blotting {#s4_10}
----------------

As described previously \[[@R31]\], aortic tissues were homogenized on ice in cell-lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na~2~EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na~3~VO~4~, 1 μg/ml leupeptin) and 1 mM PMSF. Cell was lysated with cell-lysis buffer. The protein content was assayed by BCA protein assay reagent (Pierce, USA). 20 μg proteins were loaded to SDS-PAGE and then transferred to membrane. Membrane was incubated with a 1:1000 dilution of primary antibody, followed by a 1:2000 dilution of horseradish peroxidase- conjugated secondary antibody. Protein bands were visualized by ECL (GE Healthcare). The intensity (area × density) of the individual bands on Western blots was measured by densitometry (model GS-700, Imaging Densitometer; Bio-Rad). The background was subtracted from the calculated area. We used control as 100%.

Detection of ROS productions in cells and tissues {#s4_11}
-------------------------------------------------

ROS productions in cultured cells were assayed by measuring the DHE fluorescence, combined with High Performance Liquid Chromatography (HPLC) with minor modifications as describe previously \[[@R32]\]. Briefly, cells were incubated with DHE (10 μM) for 30 min, washed, harvested and homogenized, and subjected to methanol extraction. HPLC was performed by using a C-18 column (mobile phase: gradient of acetonitrile and 0.1% trifluoroacetic acid) to separate and quantify oxyethidium (product of DHE and O~2~^-^) and ethidium (a product of DHE auto-oxidation). O~2~^-^ production was determined by conversion of DHE into oxyethidine.

To measure ROS production in the artery *in situ*, fresh frozen sections of carotid arteries were isolated from rats, and were stained with 10 μM DHE for 30 min, rinsed, and observed by fluorescent microscopy. Results were quantified using BIOQUANT Image software.

Measurement of tension development in aortic rings {#s4_12}
--------------------------------------------------

*In vivo* or *ex vivo* organ chamber study was performed as described previously \[[@R33]\]. Rats were sacrificed under anesthesia by intravenous injection with pentobarbital sodium (30 mg/kg). The descending aorta isolated by removing the adhering perivascular tissue carefully was cut into rings (3-4 mm in length). Aortic rings were suspended and mounted to organ chamber by using two stainless. The rings were placed in organ baths filled with Kreb\'s buffer of the following compositions (in mM): NaCl, 118.3; KCl, 4.7; MgSO~4~, 0.6; KH~2~PO~4~, 1.2; CaCl~2~, 2.5; NaHCO~3~, 25.0; EDTA, 0.026; pH 7.4 at 37°C and gassed with 95% O~2~ plus 5% CO~2~, under a tension of 2.0 g, for 90-minute equilibration period. During this period, the Kreb\'s solution was changed every 15 min. After the equilibration, aortic rings were challenged with 60 mM KCl. After washing and another 30 minutes equilibration period, contractile response was elicited by phenylephrine (1 μM). At the plateau of contraction, accumulative acetylcholine was added into the organ bath to induce the relaxation.

Measurements of MDA, SOD and GSH-Px {#s4_13}
-----------------------------------

The determinations of MDA content, SOD activity and GSH-Px activity in aortic tissues or serum were assayed by using commercial kits as recommend by the protocol.

Statistical analysis {#s4_14}
--------------------

All quantitative results are expressed as mean ± s.e.m. The vessel responses to Ach or SNP are expressed as percentages of pre-contractions and these data were analyzed using a two-way ANOVA followed by Bonferroni corrections. One-way ANOVA was used to compare multiple groups followed by Newman-Keuls student t-tests. Statistical analysis was conducted using IBM SPSS statistics 20.0 (IBM Corp., Armonk, NY, USA) and *P* \< 0.05 were considered as statistical significance.

SUPPLEMENTARY DATA SET {#s5}
======================

This project was supported by the National 973 Basic Research Program of China (2013CB530700), the National Natural Science Foundation of China (81320108004, 81370411, 81470591, 81570723, 81673423, and 31372409), and the Science and Technology Research Project of Henan Province (121100910300 and 132102310247). This project was also sponsored by the Program for New Century Excellent Talents in University (NCET-13-0351), the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry, and the Program of Clinical Investigation (Nanshan Group), Qilu Hospital, Shandong University (2014QLKY15). S.-X.W. is a Qilu Professional Scholar of Shandong University and a Taihang Professional Scholar of Xinxiang Medical University (505067).

**CONFLICTS OF INTEREST**

The authors confirm that there are no conflicts of interest.
